Apatinib as Second-line Treatment of Advanced Pancreatic Cancer

Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Study ID
NCT02726854
Phase
PHASE2
Status
Unknown

Conditions

  • Pancreatic Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.

Study Details

The main research purpose Evaluation of objective response Apatinib second-line treatment of advanced pancreatic cancer (ORR) and the rate of progression free survival (PFS). Objective to study the objective and exploratory secondary research To observe the Apatinib in second line treatment of advanced pancreatic cancer disease control rate (DCR), patients with overall survival (OS) benefit, treatment effects on quality of life (QOL) score and drug safety evaluation, To investigate the relationship of apatinib as second-line treatment of advanced pancreatic cancer and the expression of vascular endothelial growth factor receptor(VEGFR) in the serum

Key Dates

Start date
Apr 30, 2016
Status verified
Nov 2016
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
    Patients will be offered with Apatinib (850mg daily,orally)until their disease have progressed.

Primary Outcome Measure

PFS(Progression free survival) [ Time Frame: 8 Weeks ]

Central Contacts

Related Studies